Evidence map›Paper›PMID 42201355›Full record

SynthesisGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026

Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis.

Stamatios Lampsas, Chrysa Agapitou, Evangelos Oikonomou, Gerasimos Siasos, Panagiotis Theodossiadis, Georgios Tsivgoulis, Vaia Lambadiari, Irini Chatziralli

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Stamatios LampsasSecond Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, 1, Rimini street, Haidari, Athens, 12462, Greece.
Chrysa AgapitouSecond Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, 1, Rimini street, Haidari, Athens, 12462, Greece.
Evangelos OikonomouThird Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, "Sotiria" General Hospital, Athens, 11527, Greece.
Gerasimos SiasosThird Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, "Sotiria" General Hospital, Athens, 11527, Greece.
Panagiotis TheodossiadisSecond Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, 1, Rimini street, Haidari, Athens, 12462, Greece.
Georgios TsivgoulisSecond Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens, 12462, Greece.
Vaia LambadiariSecond Department of Internal Medicine, Research Institute and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens, 12462, Greece.
Irini ChatziralliSecond Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, 1, Rimini street, Haidari, Athens, 12462, Greece. eirchat@yahoo.gr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) has expanded dramatically worldwide, with semaglutide being one of the most widely utilized agents. Nonarteritic anterior ischemic optic neuropathy (NAION) has been associated with GLP-1RAs use from emerging pharmacovigilance data. This systematic review and meta-analysis sought to evaluate the risk of NAION in patients with type 2 diabetes mellitus (T2DM).

methodsA literature search was made up to September 2025 (PROSPERO: CRD420251155026). Results were synthesized following the PRISMA guidelines and are presented as pooled Hazard Ratios (HR) with 95% confidence intervals (CI).

resultsTwelve studies were included; eight retrospective cohorts (14,255,247 participants) were meta-analyzed, with a mean age of 59.3 ± 15.9 years and 32.7% males. Patients with T2DM using semaglutide compared to non-GLP-1RAs showed an increased risk of NAION at 1-year follow-up with a pooled HR of 3.36 (95% CI: 1.44-7.84; p < 0.001; I

conclusionThis meta-analysis indicates a significant association between semaglutide use and NAION in patients with T2DM compared to non-GLP-1RAs, with this association remaining significant even after 5-years of semaglutide use.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsOptic Neuropathy, IschemicHumansRisk FactorsSemaglutideGlucagon-Like PeptidesHypoglycemic AgentsSemaglutideGLP-1 receptor agonistsNon-Arteritic Anterior Ischemic Optic Neuropathy (NAION)SemaglutideType 2 diabetes mellitus

Identifiers

PMID42201355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.